Spotlight on Aduhelm
A story about Biogen's pricing model for its Alzheimer’s drug, Aduhelm, released in December 2021, continued to generate interest over the following months.
When approved by the US FDA in June, the drug became the first new drug to treat Alzheimer’s since 2003. However, the approval proved controversial.
Photo credit: GettyImages/Frank Brennan